INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $330,563 | -20.1% | 6,346 | -2.8% | 0.04% | -18.2% |
| Q2 2023 | $413,543 | +13.6% | 6,531 | -2.8% | 0.04% | +7.3% |
| Q1 2023 | $363,942 | +5.2% | 6,721 | +2.8% | 0.04% | -2.4% |
| Q4 2022 | $345,885 | -75.4% | 6,536 | -78.4% | 0.04% | -76.8% |
| Q3 2022 | $1,407,000 | -19.7% | 30,236 | -1.5% | 0.18% | -12.6% |
| Q2 2022 | $1,753,000 | +1.3% | 30,703 | -2.0% | 0.21% | +1.5% |
| Q1 2022 | $1,731,000 | +2.7% | 31,341 | -2.7% | 0.20% | +28.3% |
| Q4 2021 | $1,686,000 | +3.3% | 32,205 | -26.4% | 0.16% | -8.6% |
| Q3 2021 | $1,632,000 | -50.8% | 43,780 | -51.9% | 0.17% | -24.0% |
| Q2 2021 | $3,316,000 | +123.5% | 90,938 | +107.9% | 0.23% | +30.9% |
| Q1 2021 | $1,484,000 | +6.2% | 43,741 | -0.4% | 0.18% | -11.6% |
| Q4 2020 | $1,397,000 | – | 43,929 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |